Jubilant Life Sciences seeks nod to roll out remdesivir tablet
Noida-based Jubilant Life Sciences reportedly plans to launch remdesivir in a tablet form. The antiviral drug, which is being used to treat COVID-19 patients, is currently administered intravenously. According to media reports, the company has sought permission of the Drugs Controller General of India (DCGI) to launch remdesivir in a tablet form. In a meeting held on August 25, the company had presented its proposal to the DCGI. The company has given bioavailability protocol to the subject expert committee (SEC), which has been set up to evaluate proposals related to COVID-19. According to the proposal, the company is exploring the possibility of launching 20-mg sublingual tablets. Sublingual administration involves placing a drug under the tongue so that it gets dissolved and absorbed into the blood through the tissues. The SEC, which functions under DCGI, has reportedly asked for more clarity from the company on the proposal.
No comments:
Post a Comment